LENSAR LNSR
LENSAR Q2 FY25: revenue $13.9M, up 10%; diluted EPS −$0.15
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001320350-25-000004
Key figures from this report
These are the numbers LENSAR reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$13.9M+10% from $12.6M in Q2 FY2410-Q income statement, on EDGAR
- Net income−$1.8MAgainst −$9.0M in Q2 FY2410-Q income statement, on EDGAR
- Diluted EPS−$0.15Against −$0.79 in Q2 FY2410-Q income statement, on EDGAR
- Cash and cash equivalents$7.2M−14% from $8.3M in Q2 FY24Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$5.0MAgainst −$3.8M in Q2 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.
- CVRx CVRX public float $112M, Jun 30, 2025
- TriSalus Life Sciences TLSI public float $112M, Jun 30, 2025
- Shoulder Innovations SI
- KORU Medical Systems KRMD public float $119M, Jun 30, 2025
- Mobia Medical MOBI
